FDA grants breakthrough status to J&J’s nipocalimab for HDFN
The FDA granted breakthrough therapy status for J&J's nipocalimab for pregnant people at risk of haemolytic disease of the foetus and newborn.
The FDA granted breakthrough therapy status for J&J's nipocalimab for pregnant people at risk of haemolytic disease of the foetus and newborn.
What's Your Reaction?
